Comparing Statins: The SATURN Trial « Cholesterol Management 101
Links shared publicly online about this topic.
- 0total visits
Comparing Statins: The SATURN Trial « Cholesterol Management 101
View full resource at blogs.webmd.com
Tags: Heart, Heart Disease, Coronary Artery Disease, Cholesterol, Disease and Condition, disease
Most Recently Shared on October 7, 2011 at 1:19 am By:
Comparing Statins: The SATURN Trial http://t.co/7w2jaO2O via @Doc4Heart
Comparing Statins: The SATURN Trial « Cholesterol Management 101
blogs.webmd.com — “High cholesterol is at the root of many conditions, including heart disease. Michael Richman, MD, FACS is here to show you how to manage your cholesterol levels effectively.” View full resource at blogs.webmd.com
Most Recently Shared on October 7, 2011 at 1:22 am By:
Cholesterol Mgmt: Comparing Statins: The SATURN Trial http://t.co/mkiNDROu
Medical News: SATURN Statin Trial a Dead Heat - in Cardiovascular, Atherosclerosis from MedPage Today
medpagetoday.com — “Rosuvastatin (Crestor) failed to beat atorvastatin (Lipitor) for improving atheroma volume in a large head-to-head trial, the drug's manufacturer reported.” View full resource at medpagetoday.com
Most Recently Shared on September 5, 2011 at 5:32 pm By:
Roger D. Jones, PhD Doctor, Health Executive, Health Social Media, and PhD
Medical News: SATURN Statin Trial a Dead Heat - http://t.co/2CGAMXv from @medpagetoday #health #medicine
AstraZeneca Falls On Crestor Disappointment - Forbes.com
forbes.com — “Shares of pharma giant AstraZeneca are trading lower Friday, after the company announced disappointing results in a trial that compared its cholesterol drug Crestor to its chief rival. The companys Saturn study pitted Crestor against Pfizers (PFE) Lipitor.” View full resource at forbes.com
Most Recently Shared on September 2, 2011 at 8:21 pm By:
Drugs and Devices OW OW Health
AstraZeneca Falls On Crestor Disappointment: Shares of pharma giant AstraZeneca are trading lower Frida... http://t.co/ps454Kh #drug
Crestor, after setback in Lipitor trial, may take sales hit - Medical Marketing and Media
mmm-online.com — “AstraZeneca's top-selling product, Crestor (rosuvastatin), is looking shaky after results from SATURN, a head-to-head study pitting the statin against Pfizer's soon-to-go-generic Lipitor (atorvastatin), were released today, leaving the $5.7 billion drug bereft of superior efficacy boasting rights.” View full resource at mmm-online.com
Most Recently Shared on September 2, 2011 at 7:21 pm By:
Crestor, after setback in Lipitor trial, may take sales hit: AstraZeneca's top-selling product, Cresto... http://t.co/0gY19h7 from MM&M
Medical News: SATURN Statin Trial a Dead Heat - in Cardiovascular, Atherosclerosis from MedPage Today
medpagetoday.com — “Rosuvastatin (Crestor) failed to beat atorvastatin (Lipitor) for improving atheroma volume in a large head-to-head trial, the drug's manufacturer reported.” View full resource at medpagetoday.com
Most Recently Shared on September 2, 2011 at 7:07 pm By:
Roger D. Jones, PhD Doctor, Health Executive, Health Social Media, and PhD
Medical News: SATURN Statin Trial a Dead Heat - http://t.co/fcaxC3g from @medpagetoday #health #medicine
AstraZeneca's Crestor fails to best Lipitor in study - FiercePharma
fiercepharma.com — “AstraZeneca ($AZN) just lost a potential marketing edge for Crestor. In trial results announced today, the statin drug failed to best Lipitor at clearing clogged arteries, at least in a statistically Read more...” View full resource at fiercepharma.com
Most Recently Shared on September 2, 2011 at 5:05 pm By:
$AZN Saturn trial didn't pan out for Crestor. Cut arterial deposits > than Lipitor by one measure but endpoint missed http://t.co/XWgTUMP
Medical News: SATURN Statin Trial a Dead Heat - in Cardiovascular, Atherosclerosis from MedPage Today
medpagetoday.com — “Rosuvastatin (Crestor) failed to beat atorvastatin (Lipitor) for improving atheroma volume in a large head-to-head trial, the drug's manufacturer reported.” View full resource at medpagetoday.com
Most Recently Shared on September 2, 2011 at 4:07 pm By:
Patricia Grace Eldercare Expert
SATURN Statin Trial a Dead Heat: (MedPage Today) -- Rosuvastatin (Crestor) failed to beat atorvastatin (Lipitor)... http://t.co/P23nqHz
SATURN Statin Trial a Dead Heat - QualityPoint Technologies
qualitypointtech.net — “(MedPage Today) -- Rosuvastatin (Crestor) failed to beat atorvastatin (Lipitor) for improving atheroma volume in a large head-to-head trial, the drug's manufacturer reported.” View full resource at qualitypointtech.net
Most Recently Shared on September 2, 2011 at 3:45 pm By:
SATURN Statin Trial a Dead Heat: (MedPage Today) -- Rosuvastatin (Crestor) failed to beat atorvastatin (Lipitor) f... http://t.co/L9dDpr7
Medical News: SATURN Statin Trial a Dead Heat - in Cardiovascular, Atherosclerosis from MedPage Today
medpagetoday.com — “Rosuvastatin (Crestor) failed to beat atorvastatin (Lipitor) for improving atheroma volume in a large head-to-head trial, the drug's manufacturer reported.” View full resource at medpagetoday.com
Most Recently Shared on September 2, 2011 at 3:18 pm By:
SATURN Statin Trial a Dead Heat http://t.co/d4dFJZk
FDA Restricts High-Dose Statin Zocor for Cholesterol - ABC News
abcnews.go.com — “The U.S. Food and Drug Administration recommended limiting high doses of a widely prescribed cholesterol-lowering drug called simvastatin -- commonly known as Zocor -- after reviewing the results of a clinical trial that found a higher risk of muscle damage compared to patients taking lower doses of the statin.” View full resource at abcnews.go.com
Most Recently Shared on June 9, 2011 at 9:45 pm By:
Susan Scroggins Active Health Library and Health Advocate
FDA Recommends Limits to High-Dose Zocor: The U.S. Food and Drug Administration recommended limiting high doses ... http://bit.ly/jXJv3J
Highest simvastatin dose linked to increased risk of muscle injury
theheart.org — “Simvastatin 80 mg is associated with increased risk of myopathy compared with lower doses and other statins, according to an FDA review of clinical-trial and other data.” View full resource at theheart.org
Most Recently Shared on March 19, 2010 at 8:04 pm By:
Highest simvastatin dose linked to increased risk of muscle injury, FDA warns: Simvastatin 80 mg is associat... http://bit.ly/dtgJaU #ACC10
Elderly JUPITER trial study
theheart.org — “The analysis showed that adults >70 years of age had a smaller reduction in relative risk in cardiovascular events compared with those younger than 70 years old but larger absolute reductions, resulting in a lower number needed to treat, particularly for more serious adverse events, according to investigators.” View full resource at theheart.org
Most Recently Shared on September 9, 2009 at 12:52 pm By:
heartwire: Elderly patients in JUPITER benefit from statin therapy http://bit.ly/vZxuZ
Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis - Full Text View - ClinicalTrials.gov
clinicaltrials.gov — “Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on July 13, 2009 at 1:28 pm By:
M Auron MD Physician, Doctor, Pediatrician, and Internist
Esetimibe vs niacin trial stopped, but not for safety reasons -will the cheap niacin be superior??? - http://bit.ly/xeRkx
Advertisement
